resume

Not in love with this template? Browse our full library of resume templates

boy

Build your resume in 15 minutes

Use professional field-tested resume templates that follow the exact resume rules employers look for.
11

research coordinator

  • Principle administrative liaison;
  • Recruit and coordinate research subjects; 
  • Develop study protocol and procedures;
  • Organize and analyze data collected;
12

research coordinator

  • 2013 Study Coordinator for Hoffmann-LaRoche BC28034; A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar Monotherapy Compared with Placebo in Patients with Type 2 Diabetes Mellitus (T2D) Who are Drug-Naïve to Anti-Hyperglycemic Therapy.·         2013 Study Coordinator for AstraZeneca D3250C00018; A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Cortocosteroid Plus Long-acting B2 Agonist in Patients with Uncontrolled Asthma (CALIMA).·         2013 Study Coordinator for MediVector T705aUS317; A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects with Uncomplicated Influenza.·         2013 Study Coordinator for Novo Nordisk NN9535-3623; Efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes.·         2013 Study Coordinator for Bristol-Myers Squibb CV181-206; A 24-Week International, Multi-Center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy in Adult Subjects with Type 2 Diabetes who have Inadequate Glycemic Control with Diet and Exercise.·         2013 Study Coordinator for Ferring Pharmaceuticals 000080-Echo 2; A Double-Blind, Randomised, Placebo-controlled, A Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period.·         2013 Study Coordinator for Shionogi 1326V9235; A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long-term Safety of Naldemedine for the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy.·         2013 Study Coordinator for Thrombosis EN3409-309; Prospective, multicentre, international Registry of male and female patients newly diagnosed with atrial fibrillation. ·         2013 Study Coordinator for Bristol-Myers Squibb Astra Zeneca CV181-169; A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3 Trial to Evaluated the Safety and Efficacy of Add-On Therapy with Saxagliptin and Dapagliflozin added to Metformin compared to Add-On Therapy with Saxagliptin in combination with Metformin or Dapagliflozin in combination with Metformin in Subjects with Type 2 diabetes who have Inadequate Glycemic Control on Metformin Alone.·         2013 Study Coordinator for Biota BTA51-350-201; A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm study to Investigate the Efficacy and Safety of Inhaled LaninamivirOctanoateTwinCaps Dry Powder Inhaler in Adults with Symptomatic Influenza A or B Infection.·         2013 Study Coordinator Carmelina 1218.22 A multicenter, international, randomized, parallel group, double-blind, placebo-controlled cardiovascular safety & renal microvascular outcome study with linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk.·         2014 Study Coordinator Astra Zeneca D589GC00003 A phase 3, 12-week, double-blind, randomized, parallel-group, multicenter study investigator the efficacy and safety of symbicortpMDI 80/2.25 ug, 2 actuations twice daily and symbicortpMDI 80/4.5 ug, 2 actuations twice daily, compared with budesonide pMDI 80 ug, 2 actuations twice daily in children ages 6 to < 12 years with asthma·         2014 Study Coordinator Janssen&Janssen 28431754DIA4003 A randomized, multicenter, double-blind, parallel, placebo-controlled study of effects of canagliflozin on renal endpoints in adult subjects with type 2 diabetes ·         Performed lab draws on all patients